Spring Coming? EU Group Holds China To Fair Play Promises In Procurement
Executive Summary
A major European business group in China is encouraged by recent signals of further policy reforms, but says in a new report it would like to see further progress on drug and device tenders, the lifting of indirect competition restrictions, and full implementation of the central push for a level playing field for foreign firms.
You may also be interested in...
Catch Me If You Can: Knowing How To Innovate Matters In China
Given the host of recent and planned policy and regulatory changes in China, the traditional lines between multinational and local companies in the country will become increasingly blurred. These who know how to innovate in different ways in the fast-changing environment will have the most to gain, says the head of one major pharma industry trade group.
Big Pharma CEOs Descend On China: What’s The Likely Agenda?
In a major show of force, four global pharma CEOs are heading to China to participate in high-level open and closed-door discussions that are expected to include a range of policy and regulatory reform topics. Tapping into China’s push to improve health and develop an innovation-driven economy may provide new openings for their voices to be heard.
China FDA Lays Out eCTDs, Bioequivalence, Patent Linkage As Priorities
Surprise announcement by China FDA to roll out an electronic common technical document system by year-end is causing jitters in the pharma industry, but other moves to raise product quality and strengthen patent linkage seem more positive for manufacturers.